Table 2.
Baseline characteristics for included patients.
| Baseline characteristics | Control group | Low-dose group | Medium-dose group | High-dose group | p Value |
|---|---|---|---|---|---|
| (n = 121) | (n = 103) | (n = 100) | (n = 105) | ||
| Age | 56.85 ± 4.67 | 58.21 ± 5.04 | 57.95 ± 4.76 | 57.56 ± 4.72 | 0.162 |
| Gender (male/female) | 68/53 | 56/47 | 54/46 | 55/50 | 0.953 |
| BMI (kg/m2) | 20.79 ± 1.61 | 20.62 ± 1.68 | 20.76 ± 1.50 | 20.74 ± 1.84 | 0.886 |
| body temperature (°C) | 37.05 ± 0.49 | 36.80 ± 0.49 | 36.84 ± 0.58 | 36.84 ± 0.53 | 0.656 |
| Smoking history | |||||
| Often [n (%)] | 17 (14.05%) | 13 (12.62%) | 11 (11.00%) | 14 (13.33%) | 0.283 |
| Never [n (%)] | 43 (35.54%) | 38 (36.89%) | 34 (34.00%) | 51 (48.57%) | |
| Ever [n (%)] | 61 (50.41%) | 52 (50.49%) | 55 (55.00%) | 40 (38.10%) | |
| GOLD classification | |||||
| The first stage [n (%)] | 9 (7.44%) | 7 (6.80%) | 14 (14.00%) | 9 (8.57%) | 0.356 |
| The second stage [n (%)] | 76 (62.81%) | 59 (57.28%) | 48 (48.00%) | 53 (50.48%) | |
| The third stage [n (%)] | 28 (23.14%) | 30 (29.13%) | 27 (27.00%) | 31 (29.52%) | |
| The fourth stage [n (%)] | 8 (6.61%) | 7 (6.80%) | 11 (11.00%) | 12 (11.43%) | |
BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease.